Aspiration Pneumonitis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for aspiration pneumonitis. 14 active patents protecting 1 drugs from 1+ originators. First major cliff: 2032. Daily refresh.

1
Approved drugs
14
Active US patents
64/100
Avg vulnerability
—
Annual revenue covered

Originators in Aspiration Pneumonitis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Generic (originally Merck/Upjohn) 14 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating aspiration pneumonitis. Each bar = one year. Y-axis scaled to peak year (4 patents).

4
32
4
33
4
34

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Cortef
hydrocortisone
 Generic (originally Merck/Upjohn) 14 64 — 2032-11-19

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11904046 Cortef method of use 75 2043-02-23
12133914 Cortef method of use 75 2043-02-23
9717740 Cortef method of use 62 2032-11-19
9717740 Cortef method of use 62 2032-11-19
9717740 Cortef method of use 62 2032-11-19
9717740 Cortef method of use 62 2032-11-19
9675559 Cortef method of use 62 2033-01-10
9675559 Cortef method of use 62 2033-01-10
9675559 Cortef method of use 62 2033-01-10
9675559 Cortef method of use 62 2033-01-10

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9649280 Cortef method of use 62 2034-05-12
9649280 Cortef method of use 62 2034-05-12
9649280 Cortef method of use 62 2034-05-12
9649280 Cortef method of use 62 2034-05-12
9675559 Cortef method of use 62 2033-01-10
9675559 Cortef method of use 62 2033-01-10
9675559 Cortef method of use 62 2033-01-10
9675559 Cortef method of use 62 2033-01-10
9717740 Cortef method of use 62 2032-11-19
9717740 Cortef method of use 62 2032-11-19

Related